LIH scientist in the royal spotlight
On June 21st, Dr Bohn received the highly esteemed title of ‘Chevalier de l’Ordre de Mérite du Grand-Duché de Luxembourg’ from the Grand Duke of Luxembourg for his contributions to the culture of Luxembourg.
Pathology Assistant - YK0621
The Pathology Assistant is responsible for preparing specimens for Pathologist examinations and diagnosis.
Scientific Equipment Assistant - WA0521
The scientific equipment assistant is responsible for providing the continuous maintenance, support and improvement of the scientific equipment management system.
[Press release] ‘Suffocating’ cancer: a new headway in melanoma immunotherapy
Hypoxia, or the inadequate oxygenation of a tissue, is a condition occurring frequently in all solid tumours such as melanoma skin cancer. Melanoma cells are not only able to survive oxygen deprivation, but also to use it to their own advantage by hijacking the anti-tumour immune response and developing resistance mechanisms to conventional anti-cancer therapies. A key gene responsible for cancer cell adaptation to hypoxia is HIF-1α (Hypoxia Inducible Factor-1 alpha). Led by Dr Bassam Janji, head of the Tumor Immunotherapy and Microenvironment (TIME) research group at the Luxembourg Institute of Health (LIH) and in collaboration with Gustave Roussy Cancer Center in France and the Thumbay Research Institute of Precision Medicine at Gulf Medical University in the United Arab Emirates, the team used gene editing technologies to show how targeting HIF-1α could not only inhibit tumour growth, but also drive cytotoxic (toxic to cells) immune cells to the cancer tissue. This discovery provided a valuable new target to make resistant melanomas more vulnerable to available anti-cancer treatments. Their findings were recently published in the reputable ‘Oncogene Journal’.
24 June 2021 03:00 PM
WEBINAR: Lecture series Cancer Research: "Metabolic perturbations and human disease phenotypes" - Prof Ralph DeBerardinis
2021 Career Launchpad Award for LIH researcher
Dr Martyna Szpakowska, scientist within the Immuno-Pharmacology and Interactomics group of the Department of Infection and Immunity (DII) and the Tumor Immunotherapy and Microenvironment group of the Department of Oncology (DONC), was awarded a EUR 10,000 grant under the LIH Wolfgang Baertz Career Launchpad Award (Legs W. Baertz) programme at the end of May 2021. The funding will allow her to develop an innovative type of antibody that targets and neutralises a receptor with a newly-discovered role in the infiltration of cytotoxic immune cells in the tumour microenvironment and in subsequent tumour recession. This transversal and translational project, has the potential to significantly advance cancer immunotherapies
Research Associate (Neighborhood and Health) - LM0621
Project in collaboration with the Luxembourg Institute of Socio-Economic Research (LISER)
New FNR PEARL Chair: Luxembourg paves the way for a new era of healthcare digitalisation
Digitalisation is moving forward fast in every field, including medicine. But how can digital tools be integrated into healthcare processes, and how should data be visualised to personalize patient care? These are only two of many questions that Professor Dr Jochen Klucken will analyse over the upcoming five years. Supported by a 3.3 MEUR FNR PEARL Chair, Prof. Dr Klucken will develop digital health concepts for Luxembourg through a joint research programme involving the Luxembourg Centre for Systems Biomedicine (LCSB) of the University of Luxembourg, the Luxembourg Institute of Health (LIH) and the Centre Hospitalier de Luxembourg (CHL).